Raloxifene: X-Ray Scattering Reveals A New Mode Of Action For Osteoporosis Drug

Raloxifene is a U.S. Food and Drug Administration (FDA)-approved treatment for decreasing fracture risk in osteoporosis and it is effective at reducing fracture risk, but only partially by suppressing bone loss. With the use of wide- and small-angle x-ray scattering (WAXS and SAXS, respectively), researchers carried out experiments at the U.S. Department of Energy's (DOE's) Advanced Photon Source (APS) at Argonne National Laboratory that revealed an additional mechanism underlying raloxifene action, providing an explanation for how this drug can achieve equivalent clinical benefit. These data, together with complementary techniques, help define a novel mechanism by which raloxifene increases inherent bone toughness. read more

Read the whole article on

More from